{"id":946525,"date":"2026-03-24T10:27:12","date_gmt":"2026-03-24T14:27:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/"},"modified":"2026-03-24T10:27:12","modified_gmt":"2026-03-24T14:27:12","slug":"vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/","title":{"rendered":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs"},"content":{"rendered":"

\nADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity
\n<\/h2>\n
\n

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the \u201cCompany\u201d or \u201cVivoSim\u201d), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology (\u201cSOT\u201d) meeting in San Diego, CA, that its NAMkind\u2122 liver and NAMkind\u2122 Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs).<\/p>\n

When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific solutions to separate anticancer activity from unwanted cytotoxicity, the Company believes that the use of NAMkind\u2122 models becomes a powerful tool to use in conjunction with existing methods to select and improve the best ADC candidates for drug development.<\/p>\n

\n Testing of approved ADC therapies in NAMkind\u2122<\/strong>
\n models shows close correlation with clinical results<\/strong>\n <\/p>\n

VivoSim NAMkind\u2122 liver model was shown to clearly see the toxicity of liver toxic ADCs such as gemtuzumab ozogomicin and clearly showed drugs with low liver toxicity such as enfortumab vedotin as lacking liver toxicity. Issues of linker cleavage and target engagement can be studied, as differential toxicity between drugs like trastuzumab emtansine and trastuzumab deruxtecan were demonstrated with strong comparability to clinical outcomes.<\/p>\n

NAMkind\u2122 intestine models were also validated with ADCs and have the ability to detect differential effects such as antibody activity on epithelium, payload impact on epithelium, and overall ADC impact on epithelium. Permeability endpoints are sensitive to the exact chemical compound, be it ADC, antibody alone, or payload.<\/p>\n

\u201cThese ADC toxicity results show a close correlation to clinical safety outcomes,\u201d said Amar Sethi, Chief Scientific Officer at VivoSim. \u201cWe consider these models validated for ADC use and think that our partners may be able to screen out toxicities during lead candidate optimization or earlier stages, which may result in greater success in the clinic at eliminating cancers using drugs with limited side effect profiles,\u201d he continued.<\/p>\n

\u201cWith clearly demonstrated success in detecting differential toxicity in ADCs, our NAMkind models are now well-established at the cutting edge of the field,\u201d said Keith Murphy, VivoSim\u2019s Executive Chairman. \u201cWe continue to trailblaze into new modalities and empower our partners in new ways.\u201d<\/p>\n

NAMKind\u2122 liver and small intestine toxicology services are now available in the US, Europe, and via local distributor engagement across Korea and China, with VivoSim continuing to scale capacity to support expanding global demand and urgent, real-world development needs.<\/p>\n

\n About VivoSim Labs<\/strong>\n <\/p>\n

VivoSim Labs, Inc. (\u201cVivoSim\u201d and the \u201cCompany\u201d), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (\u201c3D\u201d) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (\u201cNAM\u201d) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (\u201cFDA\u201d) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

\n Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind\u2122, including the use of NAMkind\u2122 models in conjunction with existing methods to select and improve the best ADC candidates for drug development and the Company\u2019s models being well-established at the cutting edge of the field; VivoSim\u2019s partners\u2019 ability to screen out toxicities during lead candidate optimization or earlier stages, which may result in greater success in the clinic at eliminating cancers using drugs with limited side effect profiles; VivoSim\u2019s ability to trailblaze into new modalities and empower their partners in new ways; and the Company\u2019s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company\u2019s filings with the\u00a0SEC, including its Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the\u00a0SEC\u00a0on\u00a0February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of\u00a0the\u00a0United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.\u00a0<\/em>\n <\/p>\n

\n Contact(s):<\/strong>
\n
Investor Relations
info@vivosim.ai<\/a><\/u>
VivoSim Labs, Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the \u201cCompany\u201d or \u201cVivoSim\u201d), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology (\u201cSOT\u201d) meeting in San Diego, CA, that its NAMkind\u2122 liver and NAMkind\u2122 Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific … <\/p>\n

Continue reading “VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946525","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the \u201cCompany\u201d or \u201cVivoSim\u201d), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology (\u201cSOT\u201d) meeting in San Diego, CA, that its NAMkind\u2122 liver and NAMkind\u2122 Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific … Continue reading "VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:27:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs\",\"datePublished\":\"2026-03-24T14:27:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/\"},\"wordCount\":884,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/\",\"name\":\"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=\",\"datePublished\":\"2026-03-24T14:27:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/","og_locale":"en_US","og_type":"article","og_title":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk","og_description":"ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the \u201cCompany\u201d or \u201cVivoSim\u201d), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology (\u201cSOT\u201d) meeting in San Diego, CA, that its NAMkind\u2122 liver and NAMkind\u2122 Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific … Continue reading \"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-24T14:27:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs","datePublished":"2026-03-24T14:27:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/"},"wordCount":884,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/","name":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=","datePublished":"2026-03-24T14:27:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzMxOSM3NTAwMjM5IzIwMjAwODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946525"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}